Carmela Benson

Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US

ABSTRACT Background: A recent study suggested that levofloxacin significantly reduces the hospital length of stay (LOS), by 0.5 days (p = 0.02), relative to moxifloxacin in patients with community-acquired pneumonia (CAP). The current analysis evaluated the potential economic impact of this half-day reduction in LOS. Methods: A cost model was developed to estimate the impact of a half-day reduction in LOS for CAP hospitalizations in the US. CAP incidence, hospitalization rate, and costs were obtained from published studies in PubMed and from publicly available government sources. The average daily cost of hospitalization was estimated for fixed costs, which comprise 59% of total inpatient costs. Costs from prior years were inflated to 2007 US dollars using the consumer price index. A range of cost savings, calculated using inpatient CAP costs from several studies, was extrapolated to the US CAP population. Results: Using the Centers for Disease Control National Hospital Discharge estimate of 5.3 days LOS for CAP, and an average cost (2007

Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain

US) of

A Method for Imputing the Impact of Health Problems on At-Work Performance and Productivity From Available Health Data

13,009 per CAP hospitalization, a daily fixed cost of

Validation of the Hospital Anxiety and Depression Scale in Patients With Acute Low Back Pain

1448 was estimated. The resultant half-day reduction in costs associated with LOS was

Validation of the Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) in Acute Low Back Pain

724/hospitalization (range

Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis

457 to

Gastrointestinal events after opioid treatment in nonmalignant pain: Correlates of occurrence and impact on health-related quality of life

846/hospitalization). When fixed and variable costs were considered, the estimated savings were

Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate

1227.27/episode. The incidence of CAP was estimated to be 1.9% (5.7 million cases/year based on current population census), and the estimated rate of CAP hospitalization was 19.6% (1.1 million annual hospitalizations). At

Impact of Noncancer Pain on Health‐Related Quality of Life

13,009/CAP-related hospitalization, total fixed inpatient costs of

Opioids before and after initiation of pregabalin in patients with diabetic peripheral neuropathy

8.6 billion annually were projected. The half-day reduction in LOS would therefore generate potential annual savings of approximately